US Stock Insider Trading | Phathom Disclosed 2 Company Insider Transactions on March 3rd

K-LinePoet · 2026-03-20T21:35:33+00:00

Phathom Pharmaceuticals disclosed multiple insider transactions in 2026, including an executive Breedlove's sale of 964 shares on February 27. The company focuses on biopharmaceuticals for gastrointestinal diseases, with products including treatment solutions related to vonoprazan.

K-LinePoet

2026-03-20 21:35:33

Abstract generation in progress

On March 3, 2026, Phathom (PHAT) disclosed two insider trading transactions. Executive Breedlove Robert Charles sold 964 shares on February 27, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 3, 2026	Executive	Breedlove Robert Charles	February 27, 2026	Sell	964	12.56	$12,100
February 12, 2026	Executive	Cook Anne Marie	February 10, 2026	Sell	1,535	12.82	$19,700
February 12, 2026	Director	Basta Steven L	February 10, 2026	Sell	6,277	12.82	$80,500
January 23, 2026	Executive	Breedlove Robert Charles	January 21, 2026	Sell	776	13.61	$10,600
January 15, 2026	Director	Parikh Asit	January 13, 2026	Buy	8,750	10.30	$90,100
December 23, 2025	Director	Parikh Asit	December 19, 2025	Buy	8,750	10.30	$90,100
December 19, 2025	Executive	Cook Anne Marie	December 17, 2025	Sell	7,703	15.36	$118,300
December 19, 2025	Executive	Breedlove Robert Charles	December 18, 2025	Sell	230	16.28	$3,700
December 19, 2025	Director	Basta Steven L	December 17, 2025	Sell	30,000	15.36	$486,000
December 2, 2025	Director	Basta Steven L	November 28, 2025	Sell	48,400	15.62	$756,000

[Company Information]

Phathom Pharmaceuticals, Inc. was incorporated on January 9, 2018, under Delaware law. The company is a biopharmaceutical firm focused on developing and commercializing new therapies for gastrointestinal (GI) diseases. Its approved products include VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK, all containing vonoprazan, an oral small-molecule potassium-competitive acid blocker (PCAB). PCAB is a new class of molecules that inhibit stomach acid secretion. VOQUEZNA is currently the only approved PCAB available for sale in the United States.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes